Haemonetics (HAE) Sparks Confidence Following Vivasure Acquisition

Haemonetics Corporation (NYSE:HAE) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds.

On January 12, Michael Petusky from Barrington maintained his Outperform rating on Haemonetics Corporation (NYSE:HAE). He also revised his estimated price target upward from $90 to $93, implying an upside of almost 41%.

oatautta/Shutterstock.com

Petusky’s rating and target price adjustment came at the back of the company’s recent acquisition of Vivasure Medical, an Ireland-based advanced polymer implants and delivery systems manufacturer. The analyst sees this deal in a favorable light, which makes him optimistic about the stock performance.

Earlier, on December 17, Mizuho Securities analyst Anthony Petrone had also reaffirmed his Outperform rating on Haemonetics Corporation (NYSE:HAE), while increasing the price target from $75 to $90. His revisions now lead to an upside potential of over 36% from the current level.

Petrone’s revisions were part of Mizuho Securities’ adjustments across the medical devices and diagnostics space, in line with its 2026 outlook. The analyst noted that there is still room for valuations to expand further despite a rally witnessed post-Q3 announcements. He anticipates this “under a scenario where the dual AI + Cryptocurrency mega-trades remain influx with Healthcare positioned as the top defensive sector.”

Haemonetics Corporation (NYSE:HAE) offers hospital technology solutions and specializes in plasma and blood management. Some of the offerings include plasma collection systems, donor management services, and supporting software that cut down healthcare costs for patients, improve patient outcomes, and enhance blood product quality.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.